Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Travoprost Intraocular Implant Exchange in Glaucoma
NCT04615403Phase 2Completed
- Sponsor
- Glaukos Corporation
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of travoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Glaukos Corporation. Started Nov 2020; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04615403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615403.